RxDoctor Payments Data

Abagail Farmer

Family · Church Hill, TNNPI 1770166761

Payments from drug & device makers

$4,230in general payments, 2019–2025

Across 115 payments — averaging $36.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Abbott$1K
  • Novo Nordisk$611
  • Lilly USA, LLC$267
  • AbbVie$250
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$149
  • plus $477 from 10 others

What the payments were for

  • Food & beverage$4,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,230 in reported general payments places this provider in the 85th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$635
Medicare patients
14
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol133$130,420
MounjaroTirzepatide48$71,776
EliquisApixaban63$62,026
OzempicSemaglutide45$58,152
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$49,141
TrulicityDulaglutide22$36,504
LinzessLinaclotide31$31,741
JardianceEmpagliflozin22$26,142
XareltoRivaroxaban24$24,491
Tresiba Flextouch U-100Insulin Degludec42$24,198
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$24,027
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$22,748
EntrestoSacubitril/Valsartan15$15,427
SymbicortBudesonide/Formoterol Fumarate38$13,318
JanuviaSitagliptin Phosphate15$12,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,354$167,765193 claims
Lilly USA, LLCMounjaro, Trulicity$267$108,28070 claims
Novo NordiskOzempic, Rybelsus$611$69,04156 claims
PfizerEliquis$44$62,02663 claims
AbbVieLinzess$250$31,74131 claims
Boehringer IngelheimJardiance, Stiolto Respimat$19$31,60133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,706 family providers in Tennessee.

Other family in Church Hill

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →